...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Newco Ownership

I am thinking it will be interesting to see what happens once these current transactions take place. When Zenith Epigenetics becomes Zenith Capital Corp, and is then holding the RVX preferreds and the 34.4 million shares in Newco, I am somewhat hopeful that if Newco does an IPO that management of Zenith Capital Corp will distribute the shares in a public Newco to the shareholders of Zenith Capital Corp. I for one have alot of Zenith shares and, if the price was right, would probably like to be able to monetize a portion of my Zenith position. For some reason I am feeling doubtful that this is managgements plan but I will be asking that question if I make it to the Zenith AGM.

Share
New Message
Please login to post a reply